While potty training is probably a distant childhood memory, the panicked feeling of “I need to pee right now and I don’t know if I can make it to the bathroom in time” is something many adults still ...

Standard stepwise therapy for overactive bladder (OAB) begins with conservative therapies such as lifestyle interventions and behavioral approaches. Medications—anticholinergics or beta-3 agonists—are ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The novel muscarinic M3 receptor antagonist DA8010 ...

Urovant Sciences has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for vibegron, a beta-3 adrenergic agonist, for the treatment of overactive bladder (OAB) with ...

Boston Scientific acquires Valencia Technologies' eCoin bladder dysfunction device, expanding into the $30M+ overactive ...

The FDA has accepted for review the New Drug Application for vibegron (Urovant Sciences) for the treatment of patients with overactive bladder with symptoms of urge urinary incontinence, urgency, and ...

Please provide your email address to receive an email when new articles are posted on . Results from the EMPOWUR extension study presented at the virtual International Continence Society Annual ...

DEAR DR. ROACH: Is there a cure for overactive bladder? — R.H. ANSWER: The underlying reason for overactive bladder is not well understood, and although there are medications to treat symptoms, there ...

The "Overactive Bladder Treatment Market by Pharmacotherapy and Disease Type - Global Forecast to 2022" report has been added to Research and Markets' offering. The global overactive bladder treatment ...

Urovant Sciences has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for vibegron, a beta-3 adrenergic agonist, for the treatment of overactive bladder (OAB) with ...